Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Pralsetinib, trans-
Non-Small Cell Lung Carcinoma
Fudan UniversityP3B (57)
Rivoceranib
Hormone Receptor-Positive Breast Cancer
Fudan UniversityP3B (57)
Catequentinib
Breast Neoplasm
Fudan UniversityP2B (57)
Cyclophosphamide
Hormone Receptor Positive Tumor
Fudan UniversityP2B (57)
Dasatinib
Triple-Negative Breast Carcinoma
Fudan UniversityP2B (57)
ETOPOSIDE
HER2/Neu Negative
Fudan UniversityP2B (57)
ETOPOSIDE
Ovarian Carcinoma
Fudan UniversityP2B (57)
EXEMESTANE
HER2 Positive Breast Carcinoma
Fudan UniversityP2B (57)
Famitinib
Breast Neoplasm
Fudan UniversityP2B (57)
HYPOXANTHINE RIBOSIDE
Triple-Negative Breast Carcinoma
Fudan UniversityP2B (57)
Rivoceranib
Breast Neoplasm
Fudan UniversityP2B (57)
Sorafenib
Breast Neoplasm
Fudan UniversityP2B (57)
Tazemetostat
Lymphoma
Fudan UniversityP2B (57)
CIS-DIAMMINEDICHLOROPLATINUM II
Homologous Recombination Deficiency
Fudan UniversityP2/3B (57)
Huaier Granule
Triple-Negative Breast Carcinoma
Fudan UniversityP4B (56)
Entrectinib
Non-Small Cell Lung Carcinoma
Fudan UniversityP3B (56)
Famitinib
Her2-Receptor Negative Breast Cancer
Fudan UniversityP3B (56)
Fluzoparib
Her2-Receptor Negative Breast Cancer
Fudan UniversityP3B (56)
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101)
Hepatocellular Carcinoma
Fudan UniversityP3B (56)
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166
Breast Cancer
Fudan UniversityP2B (56)
ETOPOSIDE
Metastatic Prostate Carcinoma
Fudan UniversityP2B (56)
Lapatinib
Colorectal Cancer
Fudan UniversityP2B (56)
Tislelizumab
Renal Cell Carcinoma
Fudan UniversityP2B (56)
Cytosin-Arabinosid
HER2-negative Breast Cancer
Fudan UniversityP4CCC (55)
Calcium folinate pentahydrate
Radiotherapy
Fudan UniversityP2CCC (55)
Showing 151 to 175 of 615 assets
PreviousPage 7 of 25Next